Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6107393 | 0.86 | KDM4E (0.43) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL2573120 | 0.86 | BLM (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL6107394 | 0.86 | KDM4E (0.43) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL2982712 | 0.86 | BLM (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL1552723 | 0.85 | CA12 (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL1350805 | 0.85 | CA12 (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL1350802 | 0.85 | CA12 (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL13269823 | 0.84 | CTSS (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL20338607 | 0.84 | CTSS (0.50) | PPARGPPARAITGB3ITGA2BCTSK | |
| SCHEMBL1241187 | 0.84 | KDM4E (0.40) | PPARGPPARAITGB3ITGA2BCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105473575-B | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | 爱杜西亚药品有限公司 | 2017-11-24 | — | — | CN | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | PPARG 798/4885PPARA 738/4885MMP1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.